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Abstract
Background: The transition phase from inpatient to outpatient care for patients suffering from Major Depressive
Disorder represents a vulnerable period associated with a risk of depression worsening and suicide. Our group has
recently found that the sleep-wake cycle in discharged depressive patients became irregular and exhibited a drift
towards later hours, associated with worsening of depression. In contrast, an advancement of sleep phase has earlier
been shown to have an antidepressant effect. Thus, methods to prevent drift of the sleep-wake cycle may be
promising interventions to prevent or reduce worsening of depression after discharge.
Methods: In this trial, we apply a new treatment intervention, named Circadian Reinforcement Therapy (CRT), to
patients discharged from inpatient psychiatric wards. CRT consists of a specialized psychoeducation on the use of
regular time signals (zeitgebers): daylight exposure, exercise, meals, and social contact. The aim is to supply stronger and
correctly timed zeitgebers to the circadian system to prevent sleep drift and worsening of depression. The CRT is used in
combination with an electronic self-monitoring system, the Monsenso Daybuilder System (MDB). By use of the MDB
system, all patients self-monitor their sleep, depression level, and activity (from a Fitbit bracelet) daily. Participants can
inspect all their data graphically on the MDB interface and will have clinician contact. The aim is to motivate patients to
keep a stable sleep-wake cycle. In all, 130 patients referred to an outpatient service will be included. Depression rating is
blinded. Patients will be randomized 1:1 to a Standard group or a CRT group. The intervention period is 4 weeks covering
the transition phase from inpatient to outpatient care. The primary outcome is score change in interviewer rated levels
of depression on the Hamilton Depression Rating Scale. A subset of patients will be assessed with salivary Dim Light
Melatonin Onset (DLMO) as a validator of circadian timing. The trial was initiated in 2016 and will end in 2020.
Discussion: If the described intervention is beneficial it could be incorporated into usual care algorithms for depressed
patients to facilitate a better and safer transition to outpatient treatment.
Trial registration: Posted prospectively at ClinicalTrials.gov at February 10, 2016 with identifier NCT02679768.
Keywords: Major depressive disorder, Sleep, Light, Electronic self-monitoring, Clinician feedback loop, Psychoeducation,
Chronotherapeutics, Outpatient treatment
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Background
Major Depressive Disorder (MDD) constitutes a consid-
erable burden for the individual patient and for society,
ranking highest on the WHO list of diseases that esti-
mate Disability-Adjusted Life Years (DALY) [1, 2]. MDD
is common with a global prevalence of approx. 3–6% [3,
4]. The most severely depressed patients are admitted to
psychiatric inpatient wards. Even though patients im-
prove substantially during their stay they are usually still
not fully recovered when discharged [5, 6], leaving them
at risk of depression worsening, and consequent re-
admission [7–9]. The suicidal risk in recently discharged
patients with MDD has also been found to be markedly
increased [10]. Thus, newly discharged patients consti-
tute a very vulnerable group.
The presence of substantial depressive symptoms at dis-
charge necessitates immediate outpatient follow-up treat-
ment. Danish guidelines recommend that the transition
period between inpatient and outpatient treatment should
be as short as possible. It is also mandatory, according to
Danish National quality standards, for all patients to have
an appointment with a relevant outpatient health service
before discharge [11]. Patients on inpatient psychiatric
wards join a predictable and structured milieu with regu-
lar meals, physical activities, sleep schedules, medication
administration, and round-the-clock care. The transition
from inpatient to outpatient status is reported by many
patients to be difficult due to the shift from a protective
and structured supportive hospitalization environment to
being left more to themselves [12].
To this end, there is an urgent need for new tools and
treatment methods to be implemented to support pa-
tients in this transition.
Electronic self-monitoring
In recent years, an increasing number of studies have
been performed using electronic self-help interventions
for depression and anxiety disorders. In general, research
points to electronic self-help interventions as useful, and
in some cases with efficacy equal to face-to-face therapy
[13]. However, for clinical depression, therapist-assisted
treatment has been shown to be superior to predomin-
antly self-help computer-based cognitive and behavioral
interventions [14]. In depression, low education level has
been found to increase the risk of symptom deterior-
ation when using these interventions [15]. Adherence
seems to be quite high, but dependent on disease sever-
ity, treatment length and chronicity [16].
In our previous feasibility study, we developed an elec-
tronic monitoring system Daybuilder (now Monsenso
Daybuilder =MDB) for use with patients suffering from
MDD [6]. The system was found to be reliable and easy to
use, even for patients recently treated with Electroconvul-
sive Treatment. Patients had a high adherence rate and
were satisfied with the usability of the program with a Sys-
tem Usability Score of 86.2 (SD = 9.7) (100 as maximum).
This system is now used in the present study with some
minor alterations: a possibility of entering daily registra-
tion of activity (from a Fitbit bracelet), graphical display of
sleep instability, text fields to enter a qualitative descrip-
tion of sleep quality, and text fields to enter any used mea-
sures to control the sleep-wake cycle. Furthermore, the
graphical interface has been improved for better clarity of
sleep and mood patterns.
Sleep, circadian rhythms, and zeitgebers
The human circadian clock, residing in the suprachiasmatic
nuclei (SCN) of the hypothalamus, has an intrinsic period
averaging 24.2 h [17]. To synchronize with the astronomical
24-h day the period is continually adjusted through external
zeitgebers stimuli (external synchronization). Zeitgebers are
stimuli capable of synchronizing circadian rhythms such as
sleep, melatonin, temperature, heart rate, and blood pres-
sure to provide a stable 24-h rhythm (entrainment). The
strongest zeitgeber is light [18], while food [19], exercise
[20], and social contact [21], although considered as weaker
zeitgebers, can probably also modulate the circadian phase
adjustment in humans. Social zeitgebers (e.g. work sched-
ules) act directly or indirectly as they influence the timing
of meals, sleep, exercise, and outdoor light exposure. The
effect of zeitgeber stimuli is dependent on their intensity
and temporal distribution during the 24-h sleep-wake cycle.
This has been most extensively described for light where a
Phase Response Curve (PRC) [22] shows the advancing or
delaying effect of light on the circadian clock dependent on
the time of day. Entrainment by light is mediated by the ret-
ina, mainly through the intrinsic photoreceptive Retinal
Ganglion Cells (ipRGCs) to the SCN and to other brain
regions [23, 24].
The setting of peripheral clocks, for example in liver
and muscle cells [25], are orchestrated from the SCN in a
hierarchical way and influenced by sleep quality, probably
mediated through light exposure at night [26]. The exact
biological mechanism underlying the synchronization
between the SCN and peripheral clocks is not fully under-
stood but is supposed to work through the sympathetic
nervous system and through humoral signals such as hor-
mones (glucocorticoids) and cytokines [27]. Recently, we
have become aware that peripheral rhythms can be out of
synchrony with each other, and thus also out of sync with
the orchestrating SCN signals (internal desynchronization)
[28]. In depression, there is clear evidence of circadian
and seasonal rhythms dysfunction [29], clinically seen as
early morning awakening and associated diurnal variation
in mood [30], as an advancement of REM sleep within the
sleep period [31], as a seasonal recurrence of depression,
and as circadian and seasonal variation in neurotransmit-
ters [32, 33]. Desynchronization between the rhythm of
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the peripheral body clocks, for instance in muscle and
liver cells, can be brought about by changes in the timing
of exercise [34], meals [35], social activity [36], and maybe
sleep [37].
External and internal desynchronization can thus be
caused by inappropriate strength and timing of zeitgeber
signals due to depression-related alterations in circadian
behavior. This includes eating at night, avoiding daylight,
light at night, or social isolation with alterations in sleep
schedule [38].
Sleep disturbances are present in 50–90% of patients
with depression [39]. The biological basis for sleep dis-
turbances in depressed patients are not fully elucidated,
but there is evidence for a circadian component such as
misaligned morning cortisol increase [40], diurnal vari-
ation in mood with evening improvement, staying up
late [41], and even inappropriate light habits [42]. Forced
changes in the timing of the sleep-wake cycle are often
linked to corresponding changes in depression severity.
Thus, a sleep-phase delay has been shown to worsen de-
pression [43], and sleep phase advance and sleep
deprivation have a well-established antidepressant effect
[44, 45]. Furthermore, daytime naps induce hour-long
mood drops in a large proportion of depressed patients
[46]. Our usability study, using electronic monitoring
that documented sleep patterns over a four-week period
in patients recently discharged from a mental health hos-
pital, found a day-to-day highly variable sleep-wake cycle
with gradually delayed sleep and unstable mood [6].
Therefore, enforcement and timing of zeitgebers with
a focus on the regulation of the sleep-wake cycle present
itself as a possible new treatment method. In this study
we will help patients to attain a time-structured environ-
ment with regularly timed zeitgeber stimuli: daylight ex-
posure, exercise, meals, and social contact, to sustain a
stable sleep cycle. We have coined this newly proposed
intervention: Circadian Reinforcement Therapy (CRT).
Objectives
The aim of this study is to prevent worsening of depres-
sion in patients with MDD after discharge from inpatients
psychiatric wards. We hypothesize that the CRT interven-
tion will help patients to recover faster and reduce the
likelihood of relapse in the period after discharge.
Design
The trial protocol is reported according to the SPIRIT
statement of randomized trials of nonpharmacologic
treatment [47]. The trial is a four-week, randomized,
controlled, single-blind, parallel-group trial with a bal-
anced allocation ratio (1:1) of adult patients diagnosed
with MDD. Patients will be randomized to either a) a
Standard group consisting of electronic self-monitoring
and usual care at an intensive outpatient service (IOS),
or to b) a CRT group using the CRT method with elec-
tronic monitoring and usual care at the IOS. Patients are
psychometrically assessed at baseline and after 4 weeks.
The trial investigates the possible effect of CRT on de-
pression. All patients will self-monitor with the MDB
system and receive usual care at the IOS. The design of
the control group (Standard group) was chosen based
on the necessity for the intended sample at IOS to have
access to qualified and adequate treatment. Thus, pla-
cebo treatment was not an option. As we were interested
in the isolated effect of the CRT intervention, we opted
that both study groups should use the MDB system and
receive treatment at the IOS.
Methods (participants, interventions, and
outcomes)
Study setting
The first patient was enrolled in the study in September
2016 and currently (April 2019), a total of 64 patients
have been included. With an expected inclusion rate of
4 patients per month, last patient last visit will be
reached July 2020.
The study is conducted at the IOS, a service receiving
depressed patients newly discharged from inpatients
wards. Treatment is performed by a multidisciplinary
team of psychiatrists, nurses, a psychologist, a physio-
therapist, and a social worker and includes consultation,
medication, psychoeducation, cognitive behavioral ther-
apy, body awareness therapy, and physical exercise.
Eligibility criteria
All patients referred to the IOS will be screened for eli-
gibility and invited to take part in the study. The eligibil-
ity criteria were chosen to represent a broad sample of
the patient group to maximize the generalizability of the
study results. Eligibility criteria are: participants must be
18 years or older, must have a DSM-IV diagnosis of
MDD, and must have given informed consent. Exclusion
criteria are patients at risk of suicidal behavior (corre-
sponding to a score of 2 or above on the Hamilton de-
pression rating scale item 3), abuse of alcohol or illegal
substances or comorbid dementia or other brain disor-
ders that might hamper the use of the MDB system, bi-
polar disorder, and psychotic depression. The eligibility
will be evaluated through case files and from interviews
with the patients.
Interventions
Monsenso Daybuilder and Fitbit description
The MDB system has been specifically developed for pa-
tients suffering from depression in a joint collaboration
between software engineers, psychiatrists, and patients
[48]. The system can be accessed from all devices using
an internet browser. Participants are provided with an
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iPad and a Fitbit bracelet (version Charge HR). Partici-
pants will enter the Fitbit count into the MDB system
where it will be displayed along with the other registra-
tions. Each participant is allocated a unique username and
password. Participants get access to registrations through
a patient interface and investigators through a separate
clinician interface. Both interfaces display a similar graph-
ical representation of entered data (see Fig. 1). Patients
will be asked to self-assess their sleep and mood twice
daily: 0–30min after waking up, and 0–30min before go-
ing to sleep – and enter it into the MDS.
Morning self-assessments: sleep onset, wake-up time,
sleep quality score, number of nighttime awakenings,
unlimited qualitative description of their sleep episode,
and morning depression severity.
Evening self-assessments: daytime naps with timing
and duration of each nap, activity from the Fitbit (the
Fitbit resets the activity count at midnight), medication
compliance (yes or no), evening depression severity, de-
pression severity as an average of the last 24 h, and un-
limited qualitative description of zeitgeber strategies that
they have been using for the last 24 h in order to keep a
stable sleep-wake cycle (CRT group only). Regarding de-
pression severity, patients are instructed to evaluate their
depression based on the DSM-IV diagnostic items for
MDD. These item descriptions are written on the inter-
face next to the data entry tab: “depressed mood, dimin-
ished interest, significant weight or appetite changes,
insomnia or hypersomnia, agitation or retardation, loss
of energy or tiredness, feelings of worthlessness or guilt,
difficulties in concentrate, and suicidal ideations”. All
quantitative parameters are scored from zero to 10 (10 is
best).
The Fitbit bracelet enables the collection of activity
and heart rate. These will be investigated as a predictor
for antidepressant response and as markers of the circa-
dian rhythm.
Procedures for the Standard group
After an introduction to the MDB system and the Fitbit
bracelet, participants will enter data into the system
daily in a four-week period. Participants will receive a
weekly telephone call from the investigator evaluating
(a) experience with the MDB system, (b) suicidal idea-
tions, (c) side effects of medications, (d) worsening of
depression, and (e) compliance with data entry. Patients
will be reminded to contact either the IOS or the psychi-
atric emergency unit if they experience aggravation in
depressive symptoms.
Fig. 1 An example of a graphic presentation in the Monsenso Daybuilder System, that can be viewed simultaneously by the patient and the clinician. In
this example only mood, sleep and activity are shown. Sleep is visualized as a blue ribbon with the lower border representing sleep-onset and the upper
border wake-up time. Mood is shown as a red line with diamond symbols with scores from zero to 10 (10 = best). Activity (=Exercise) is shown as yellow
dot symbols representing accumulated 24-h counts measured by a Fitbit charge HR bracelet
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Procedures for the CRT group
Participants in the CRT group will enter data into the
MDB system, as in the standard group, but an extra
module is added to the system, using a graphical depic-
tion of a manometer measuring day-to-day variation in
sleep onset, and another manometer measuring changes
in sleep midpoint. The manometers serve as a psychoe-
ducational tool for the patients to spot and adjust
changes in their sleep timing.
The CRT intervention also includes an individual CRT
psychoeducational session at baseline and in one of the
next two subsequent days, and with booster sessions at
the weekly telephone calls. The initial two CRT sessions
are provided by the investigator as an individual 1-h ses-
sion including an introduction to the CRT principles
using a full written CRT guide, and a leaflet version, fo-
cusing on how participants can incorporate adequate
and timed zeitgeber stimuli into their daytime activities
regarding daylight exposure, exercise, meals, and social
contact. The investigator then helps the participant to
fill in a schedule called “basic strategy for daily struc-
ture” and provides the participant with a paper and pen
diary “The Chrono schedule” where the daily timing of
daylight exposure, exercise, meals, and social contact
must be noted for the morning, afternoon and evening
time-period (see Fig. 2). Finally, the investigator helps
the participant to formulate and write down three
problems, within the CRT area, they want to work with,
in the following 4 weeks, for example: how to achieve an
earlier bedtime, how to achieve more daylight, and how
to achieve more regular meals.
The Fitbit will be set to a goal of 4000 steps, alerting
with a vibration when this is reached, to nudge partici-
pants to be more active.
The weekly telephone calls will cover the same ele-
ments as in the Standard group, supplemented with a
discussion of management of the three identified prob-
lems, patterns in the Chrono schedule, and in the graph-
ical representation of self-monitored data. This will
enable a discussion on how to strengthen zeitgeber stim-
uli and advance the sleep period and point out any pat-
terns in the graphical display between for example
delayed sleep and mood worsening.
Participants’ data registrations, in the MDB system,
will be evaluated daily (Monday to Friday) by the investi-
gator. Patients will be contacted if data is missing or if
the registrations show predefined trigger signs of aggra-
vation of depression or unstable sleep patterns (de-
scribed in Table 1).
Concomitant care
All participants will be following the standard IOS treat-
ment program as described above.
Fig. 2 The Chrono schedule used to implement Circadian Reinforcement Therapy (CRT). Patients register daily timing of meals, social interaction,
exercise and daylight exposure
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Outcomes
Diagnostic measures
The Mini International Neuropsychiatric Interview
(M.I.N.I.) 4.0 (Danish version) is used for diagnosis. This
is a short, structured diagnostic interview based on the
DSM-IV diagnostic system, and will be conducted to
confirm depression diagnosis, assess comorbidity, and
any contraindications for participation in the trial [49].
Investigators are certified in the use of the M.I.N.I.
instrument.
Psychometrics and sociodemographics
Sociodemographic data are collected at baseline together
with a treatment outcome expectancy rating. Psychomet-
ric assessments are performed at baseline and at the
endpoint visit. Rating window is set as last 3 days for all
instruments except for the Pittsburgh Sleep Quality
Index (PSQI) that covers the last month. The severity of
depression is assessed by the Hamilton Depression
Rating scale, 17 item version, which includes the core
symptoms of depression (HAM-D6), and the Bech-
Rafaelsen Melancholia Rating Scale (MES) focusing
more on the cognitive symptoms of depression [50, 51].
The Hamilton rater is blinded to treatment allocation
and is trained in the use of the HAM-D17 by repeated
groups ratings with co-researchers. Self-assessed depres-
sion severity is measured by the Major Depression In-
ventory (MDI), a 10-item questionnaire covering both
the ICD-10 and the DSM-IV diagnostic criteria for de-
pression [52]. The response categories of each item are
from “at no time” (0) to “all the time” [5], with a score
range from 0 (zero) to 50 and a cut-off score of 21 for
mild depression, 26 for moderate depression and 31 for
severe depression. The WHO-5 Wellbeing index is used
as a measure of Quality of life [53]. The WHO-5 consist
of 5 items, each rated from “all of the time” (5) to “at no
time” (0). The raw score is calculated by summing items
multiplicated by four, giving a score range from 0 to 100,
where 0 is worst possible and 100 is the best possible
quality of life. The Morningness-Eveningness Question-
naire (MEQ) is a 19 items self-assessed questionnaire
constructed to assess chronotype. A score below 42 indi-
cates “evening type” and a score above 58 indicates
“morning type”; and a score between 42 and 58 indicates
“intermediate type” [54]. Sleep quality is assessed by the
PSQI containing 11 self-reported items. These items are
transformed into 7 “component scores” , and a “global
score”. The components scores are “Subjective sleep
quality (1)”, “Sleep latency (2)”, “Sleep duration (3)”,
“Sleep efficiency (4)”, “Sleep disturbances (5)”, “Sleep
medication (6)” and “Daytime dysfunction (7)”. A “Glo-
bal Score” of 5 or above indicates poor sleep quality
[55]. The System Usability Score (SUS) is used to evalu-
ate the usability of the MDB system [56].
Biochemical assessments
The Dim Light Melatonin Onset (DLMO) will be deter-
mined by saliva sampling every 45 min in the evening
from 5 h before expected bedtime until 1 h after ex-
pected bedtime at baseline and endpoint (6 samples at
each assessment day). The patient will collect samples at
home according to a delivered 1-page guideline. The im-
portant rule from this guideline is to wear orange gog-
gles (provided by investigators) for the entire 6-h
episode of saliva sampling (to prevent suppression of
melatonin secretion by blue light). The samples will be
refrigerated and kept frozen until the melatonin assay.
All samples obtained from a single patient will be
assayed in the same batch to avoid inter-assay variability.
The DLMO, a marker of circadian phase, is determined
as the time point where melatonin production rises [57]
using the hockey-stick method [58]. Patient-reported
sleep data is used to calculate sleep midpoint. From
sleep midpoint and DLMO, we can calculate the Phase
Angle Difference (PAD) as a measure of entrainment
[59]. The normal value of PAD is 6 h [56]. We expect
patients to have a phase delayed DLMO relative to sleep
midpoint with a PAD of approximately 5 h.
Table 1 Triggers for clinicians telephone call based on inspecting of daily self-assessments in the Monsenso Daybuilder system
Parameter Evaluation criteria for feedback
Sleep (one of these) ✓More than 10 or less than 4 h sleep a night
✓A drop-in sleep quality of 4 or above (from 8 to 4 e.g.)
✓Variation of 3 h or more between two adjoining days in wake-up time or sleep onset
✓More than 3 awakenings a night for two nights
✓Late sleep for 3 days – with sleep onset after midnight and wake up time after 9 am
Depression severity (on of these) ✓Drop in daily depression score of 3 or more (e.g. from 8 to 5)
✓A daily depression score of 2 or less
✓Morning depression score of 2 or less
Medication ✓More than 1 day without medication registration
Activity ✓More than 1 day without activity registration
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Ranking of outcomes
The primary outcome is the change in interviewer rated
levels of depression (blinded) measured by the Hamilton
Depression Rating scale 17-item version. The secondary
outcome is the change in self-assessed depression level
based on the scores on the Major Depressive Inventory.
The tertiary outcome is the change, in minutes, of the
Phase Angle Difference (PAD) on the subset of patients
assessed with Dim Light Melatonin Onset (DLMO).
Explorative outcomes are: (a) changes in quality of life
based on changes on the WHO-5 wellbeing scale, (b)
self-rated depression severity from the MDB system (c)
self-rated sleep quality from the MDB system, (d) chron-
otype from the MEQ and, (e) sleep quality assessed by
the Pittsburgh Sleep Quality Index, (f ) Fitbit pulse and
activity data.
Participants timeline
Participants are included while still on the inpatient
ward or at latest 3 weeks after initiating treatment at the
IOS and are followed for 4 weeks (see Spirit flow dia-
gram in Fig. 3).
Sample size
Sample size calculations were done using the SAS 9.4
software.
The sample size for the primary outcome was calculated
from an expected HAM-D17 mean score of 18 at baseline,
a decrease to a score of 13 in the Standard group arm and
to 10 in the CRF group, an expected pooled standard devi-
ation of 6, an alpha level of 0.05 and a power of 0.80: a
total of 128 participants is needed.
The sample size for the secondary outcome was calcu-
lated from an expected MDI mean score of 27 at base-
line, a decrease to 22 in the Standard group and to 16 in
the CRF group, with an expected pooled standard devi-
ation of 12, an alpha level of 0.05 and a power of 0.80: a
total of 128 participants will be needed.
The sample size for the tertiary outcome was calcu-
lated from an expected PAD of 5 h in the CRT group at
baseline (a phase delay) normalizing to 6 h at endpoint,
an unchanged PAD of 6 h in the Standard group, a PAD
standard deviation of 80 min, an alpha level of 0.05 and
power of 0.80: a total of 58 patients will be needed. We
will collect saliva samples in 58 consecutive patients
from participant randomization number 72.
Recruitment
When the IOS receive a referral, the attending physician
will pass on information from the patient’s case file to
the investigator, regarding age, dementia, psychotic epi-
sodes, and bipolar illness. If no exclusion criteria are
present, investigators will contact the referring ward.
Methods (assignment of interventions)
Allocation
The randomization list was created from a computer
randomization solution (http://www.randomization.
com), by a person without any other connection to the
trial. In all, 152 randomization numbers have been cre-
ated allocating into either the CRT group or the Stand-
ard group, with no stratification factors. The
randomization list is only accessible to the investigator
responsible for randomization. The randomization se-
quence has been transferred to code-letters, stored in
opaque envelopes in a locked cabinet. Block size is
blinded for investigators. Primary investigator will enroll
and assign participants to interventions. The patient will
be allocated to the next study number and given an
opaque allocation envelope containing information of
trial group allocation: Standard group or CRT group.
Blinding
The rater performing the Hamilton interview is blinded
to treatment allocation and has no other association
with the study. We do not consider it necessary in any
circumstances to reveal a participant’s allocated inter-
vention during the trial.
Methods (data collection, management, and
analysis)
Data collection
All assessments are carried out by psychometrically
trained investigators (ASA, KM). The Hamilton ratings
are conducted by a certified Hamilton rater blinded for
study group allocation (AP). The patients are instructed
not to reveal group allocation to the rater. Trial duration
is 4 weeks, including baseline assessment (pre-interven-
tion) and final assessment (post-intervention). Patients
not entering data into the MDB system for 2 days will be
contacted by phone. Patients not showing up at end-
point visit will be contacted for a new appointment.
Only patients with an endpoint Hamilton assessment are
considered as completers.
Data management
Data from the MDB application is exported from the
website after each completed patient, as an excel file. All
data files are stored on a secure logged server approved
by the Danish Data Protection Agency. Paper and pencil
records are stored in a locked room in a locked cabinet.
All data will be checked for range and missing values.
Statistical methods
Sociodemographics, scale scores, self-assessed outcomes,
Fitbit data, and DLMO timepoints, will be described by
summary and frequency statistics. Comparisons between
groups will use parametric or non-parametric analyses
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according to normality distribution of data. Self-assessed
daily data (depression, activity, and sleep) will be analyzed
within a Mixed Model Repeated Measures analysis with a
Random-effects Regression Model (RRM) [60]. Hamilton
scale scores will be analyzed in a general linear model with
baseline control. No interim analyses are planned.
Methods (monitoring)
Data monitoring and auditing
According to Danish law, only drug trials are required
to comply with Good Clinical Practice guidelines. Data
analyses will be supervised by a trained statistician. The
project is subject to auditing from the regional ethical
committee.
Harm
We do not expect that the study will expose any partici-
pants to serious adverse advents or reactions as their
usual clinical management is maintained. All adverse
events will be recorded and rules for reporting of serious
adverse events and serious adverse reactions will be ad-
hered to. Any harm due to the study procedures is cov-
ered by the Danish Patient Compensation Association.
Ethics and dissemination
Research ethics approval
The study was approved by The Regional Committee on
Health Research Ethics (H-15013943) and the Danish Data
Protection Agency (2012–58-004/ RHP-20016-0016). All
participants will provide a signed informed consent before
Fig. 3 SPIRIT flow chart of study procedures
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enrollment into the study. Informed consent will be ob-
tained by the primary investigator. The project will be
stopped if participants develop serious side effects or if the
MDB system becomes unavailable. Patients can leave the
study at any time at their own discretion.
Consent or assent
The staff at the inpatient ward, or at the IOS, will ask
the referred patient whether to consent to an informa-
tion meeting about the study. The patient will receive
written and oral information regarding the trial from an
investigator. The patient will be asked to decide on par-
ticipation within 2 days. If the patient accepts, the in-
formed consent will be signed, and the inclusion and
baseline assessments will begin.
Confidentiality
Patient confidentiality will be secured by anonymous
participant identification on all pen-and-paper sheets
and in electronic files. The participant identification list
is stored on a secure, password protected server, only ac-
cessible to investigators. MDB data are stored on a se-
cure logged server where all data is secured by a unique
identifier with data entry logs and edit trail.
Access to data
The final data set will be accessible to all persons in the
project group. Data analyses will be supervised by a
qualified statistician.
Dissemination policy
Results will be communicated as papers in peer-reviewed
international journals, as posters, and as oral presentations
at international symposia. All data whether negative, posi-
tive or inconclusive will be reported in full. All members
of the project group are co-authors with a pre-arranged
order. No professional writers will be used. Depending on
the journal of publication, part of the protocol, statistical
code, and dataset will be publicly available.
Discussion
In the review by Van’t Hof from 2009, several advantages
and disadvantages for electronic self-help interventions
[61] are listed. These include: saving therapist time, let-
ting the patients work at their own pace in their own
home, avoiding social stigma by attending psychiatric
services, can function as a first step to enter treatment,
securing the anonymity of the patient, monitoring pa-
tient progress more closely. A number of disadvantages
are listed including: the inability of self-help programs to
take care of comorbidity, the clinical information based
on non-verbal and verbal clues are lost, systems do not
allow a proper diagnostic interview making misclassifica-
tion and wrong treatment a risk, lack of response to
complications during treatment unless the system in-
cludes clinician feedback, and some patients might not
be able to handle electronic systems.
Our own experience with these systems, when used as a
tool in depressed patients in an inpatient ward, is quite
similar [6]. Electronic self-monitoring can give flexibility
for patients that can use the programs whenever it suits
them, patients can use the electronic self-monitoring sys-
tem to prepare for a consultation with a psychiatrist, and
progress or worsening can be co-monitored by patient
and clinician and adequate steps can be taken earlier. Dis-
advantages are lack of face-to-face interactions, the risk of
missing important symptoms that are not monitored,
nonverbal communication between patient and psych-
iatrist is missing, no assessment of psychomotor inhibition
and mood reactivity and some patients find it difficult to
handle the electronic systems which can increase feelings
of worthlessness.
The design of this trial is not a standard RCT with
placebo control, but rather usual care with two different
add-on treatments: electronic monitoring in the Stand-
ard group and electronic monitoring and Circadian
Reinforcement Therapy in the CRT group. Participants
might gain from participating in both treatment groups
from using the MDB system that enables them to gain
insight into their symptoms making some sort of em-
powerment likely. This might limit the possibility to show
any superiority of the CRT method in these patients with
more severe depression, where improvement is very slow.
The effect of the CRT method has not previously been
tested, and we cannot be certain that the CRT interven-
tion will aid patients in the transition phase from inpatient
to outpatient status. We have concerns whether patients
in this phase are too burdened by depression symptoms to
be able to integrate new knowledge and habits into their
daily lives. Regarding the electronic monitoring system,
our experience is that any procedure in this phase needs
to be very user-friendly and adaptable. We have designed
the MDB system to comply with these conditions, but we
cannot know to what extent these patients can manage to
self-assess their state and look at the graphical interface to
deduce patterns and make changes to their daily activities
and sleep habits.It is a limitation of the trial that we only
include patients having been admitted to an inpatient
ward. The reduces generalizability, as we cannot know
whether patients with less severe depression might react
differently to the intervention. It is also a limitation that
the trial only covers a period of 4 weeks. Finally, the tech-
nology has already advanced since the design of the MDB
system and currently, the direction is towards app-based
systems that can be used directly on Smartphones.
We hope that the CRT in combination with the MDB
system will prove to be an efficacious new non-pharma-
cological treatment for patients with depression building
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on empowerment by giving patients new monitoring
tools, physiological and psychological insights, the op-
portunity to be more involved in their own treatment,
and more access to clinicians. If the CRT intervention
proves successful it might be used for longer durations
to give more a sustained impact.
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